NGL Fine-Chem growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024
+36.0%+8.7%+21.8%
+114.6%−36.4%+55.2%
+148.0%−48.5%+80.8%
+127.8%−48.9%+101.6%
+127.8%−48.9%+101.6%
+25.9%+21.9%+23.8%
+16.6%+7.5%+18.0%
+20.9%+75.0%−42.0%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

NGLFINE₹2,610.60

NGL Fine-Chem Limited

· Pharma & Health
₹ CrorePeersSYNCOMFJAGSNPHARMHESTERBIOAMRUTANJANWINDLASINDOCOSAIPARENTMcap ₹1,613 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—+21.8+8.7+36.0—
EBITDA Growth—+55.2-36.4+114.6—
EBIT Growth—+80.8-48.5+148.0—
Net Income Growth—+101.6-48.9+127.8—
EPS Growth—+101.6-48.9+127.8—
Total Assets Growth—+23.8+21.9+25.9—
Total Equity Growth—+18.0+7.5+16.6—
Cash from Operations Growth—-42.0+75.0+20.9—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.